Programmed symptoms: Disparate effects united by purpose

Current Rheumatology Reviews

Volumn 11, Issue 2, 2015, Pages 116-130

  Gracely, Richard H ^a   Schweinhardt, Petra ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Autonomic; Central sensitivity syndromes; Fibromyalgia; Functional somatic disorders; Hypothalamic pituitary adrenal axis; Illness response; Immune; Protective homeostasis; Purposeful feeling state; Stress

Indexed keywords

ALPHA INTERFERON; BETA 2 ADRENERGIC RECEPTOR; CATECHOL METHYLTRANSFERASE; INTERLEUKIN 6; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ARTICLE; AUTONOMIC NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM SENSITIZATION; CENTRAL SENSITIVITY SYNDROME; FATIGUE; FIBROMYALGIA; HUMAN; HUMAN T-LYMPHOTROPIC VIRUS 1; HYDROCORTISONE BLOOD LEVEL; HYPERALGESIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE SYSTEM; IRRITABLE COLON; NEUROPATHIC PAIN; PAIN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; TEMPOROMANDIBULAR JOINT DISORDER; V; VIRUS INFECTION; VULVODYNIA; ADRENERGIC SYSTEM; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; CHRONIC PAIN; DIFFERENTIAL DIAGNOSIS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PATHOPHYSIOLOGY;

CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; CENTRAL NERVOUS SYSTEM SENSITIZATION; CHRONIC PAIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNE SYSTEM; PITUITARY-ADRENAL SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 84937154629     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/1573397111666150619095125     Document Type: Article

References (154)

1. Kanaan RA, Lepine JP, Wessely SC. The association or otherwise of the functional somatic syndromes. Psychosom Med 2007; 69(9): 855-9.
2. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33(2): 160-72.
3. Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 2011; 38(6): 1113-22.
4. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterol 2006; 130(5): 1377-90.
5. Gracely RH, Grant MA, Giesecke T. Evoked pain measures in fibromyalgia. Best Pract Res Clin Rheumatol 2003 Aug; 17(4): 593-609.
6. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain 2003; 105(3): 403-13.
7. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum 2008; 37(6): 339-52.
8. Harvey SB, Wessely S. How should functional somatic syndromes be diagnosed? Int J Behav Med 2013; 20(2): 239-41.
9. Nimnuan C, Rabe-Hesketh S, Wessely S, Hotopf M. How many functional somatic syndromes? J Psychosom Res 2001; 51(4): 549- 57.
10. Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? Lancet 1999; 354(9182): 936-9.
11. Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007; 36(6): 339-56.
12. Kanaan RA, Armstrong D, Wessely SC. The function of 'functional': a mixed methods investigation. J Neurol Neurosurg Psychiatry 2012; 83(3): 248-50.
13. Kroenke K. Physical symptom disorder: a simpler diagnostic category for somatization-spectrum conditions. J Psychosom Research 2006; 60(4): 335-9.
14. Geisser ME, Glass JM, Rajcevska LD, et al. A psychophysical study of auditory and pressure sensitivity in patients with fibromyalgia and healthy controls. J Pain 2008; 9(5): 417-22.
15. Hollins M, Harper D, Gallagher S, et al. Perceived intensity and unpleasantness of cutaneous and auditory stimuli: an evaluation of the generalized hypervigilance hypothesis. Pain 2009; 141(3): 215- 21.
16. Lopez-Sola M, Pujol J, Wager TD, Garcia-Fontanals A, Blanco- Hinojo L, Garcia-Blanco S, et al. Altered functional magnetic resonance imaging responses to nonpainful sensory stimulation in fibromyalgia patients. Arthritis Rheumatol 2014; 66(11): 3200-9.
17. McDermid AJ, Rollman GB, McCain GA. Generalized hypervigilance in fibromyalgia: evidence of perceptual amplification. Pain 1996; 66(2-3): 133-44.
18. Schweinhardt P, Sauro KM, Bushnell MC. Fibromyalgia: a disorder of the brain? The Neuroscientist 2008; 14(5): 415-21.
19. Hoffert MJ, Greenberg RP, Wolskee PJ, et al. Abnormal and collateral innervations of sympathetic and peripheral sensory fields associated with a case of causalgia. Pain 1984; 20(1): 1-12.
20. Gracely RH, Lynch SA, Bennett GJ. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain 1992; 51(2): 175-94.
21. Giesecke T, Gracely RH, Grant MA, et al. Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum 2004; 50(2): 613-23.
22. Woolf CJ. What to call the amplification of nociceptive signals in the central nervous system that contribute to widespread pain? Pain 2014; 155(10): 1911-2.
23. Ceko M, Bushnell MC, Gracely RH. Neurobiology underlying fibromyalgia symptoms. Pain Res Treat2012; 2012: 585419.
24. Martenson ME, Cetas JS, Heinricher MM. A possible neural basis for stress-induced hyperalgesia. Pain 2009; 142(3): 236-44.
25. Imbe H, Okamoto K, Donishi T, Senba E, Kimura A. Involvement of descending facilitation from the rostral ventromedial medulla in the enhancement of formalin-evoked nocifensive behavior following repeated forced swim stress. Brain Res 2010; 1329: 103- 12.
26. Rivat C, Becker C, Blugeot A, et al. Chronic stress induces transient spinal neuroinflammation, triggering sensory hypersensitivity and long-lasting anxiety-induced hyperalgesia. Pain 2010; 150(2): 358-68.
27. Wiertelak EP, Roemer B, Maier SF, Watkins LR. Comparison of the effects of nucleus tractus solitarius and ventral medial medulla lesions on illness-induced and subcutaneous formalin-induced hyperalgesias. Brain Res 1997; 748(1-2): 143-50.
28. Heinricher MM, Neubert MJ, Martenson ME, Goncalves L. Prostaglandin E2 in the medial preoptic area produces hyperalgesia and activates pain-modulating circuitry in the rostral ventromedial medulla. Neuroscience 2004; 128(2): 389-98.
29. Heinricher MM, Martenson ME, Neubert MJ. Prostaglandin E2 in the midbrain periaqueductal gray produces hyperalgesia and activates pain-modulating circuitry in the rostral ventromedial medulla. Pain 2004; 110(1-2): 419-26.
30. Neubert MJ, Kincaid W, Heinricher MM. Nociceptive facilitating neurons in the rostral ventromedial medulla. Pain 2004; 110(1-2): 158-65.
31. Price DD, Craggs JG, Zhou Q, Verne GN, Perlstein WM, Robinson ME. Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models, and neuroimaging. NeuroImage 2009; 47(3): 995- 1001.
32. Staud R, Nagel S, Robinson ME, Price DD. Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: a randomized, double-blind, placebo-controlled study. Pain 2009; 145(1-2): 96-104.
33. Wall PD. On the relation of injury to pain. The John J. Bonica lecture. Pain 1979; 6(3): 253-64.
34. Jänig W, Levine JD. Autonomic, Endocrine and Immune Interactions in Acute and Chronic Pain. In: Stephan B. McMahon MK, Irene Tracey, Dennis C, Turk, editor. Wall and Melzack's Textbook of Pain Elsevier Saunders 2013. p. 198-210.
35. Selye H. A syndrome produced by diverse nocuous agents. J Neuropsychiatry Clin Neurosci 1998; 10(2): 230-1.
36. Dantzer R, Kelley KW. Twenty years of research on cytokineinduced sickness behavior. Brain Behav Immun 2007; 21(2): 153- 60.
37. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature reviews Neuroscience 2008; 9(1): 46-56.
38. Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988; 12(2): 123-37.
39. Johnson RW. The concept of sickness behavior: a brief chronological account of four key discoveries. Vet Immunol Immunopathol 2002; 87(3-4): 443-50.
40. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002; 25(3): 154-9.
41. Watkins LR, Maier SF. The pain of being sick: implications of immune-to-brain communication for understanding pain. Ann Rev Psychol 2000; 51: 29-57.
42. Selye H. Stress in health and disease. Reading MA: Butterworth; 1976.
43. Bernard C. Lectures on the phenomena common to animals and plants. . Trans Hoff HE GR, Guillemin L, editor. Springfield (IL): Charles C Thomas; 1974.
44. Cannon W. The Wisdom of the Body. NY: W. W. Norton; 1932.
45. Noakes TD. Fatigue is a Brain-Derived Emotion that Regulates the Exercise Behavior to Ensure the Protection of Whole Body Homeostasis. Frontiers Physiol 2012; 3: 82.
46. Miller NE. Some psychophysiological studies of motivation and the behavioral effects illness. Bull Brit Psychol Soc 1964; 17: 1-21.
47. Kelley KW, Bluthe RM, Dantzer R, et al. Cytokine-induced sickness behavior. Brain Behav Immun 2003; 17 Suppl 1: S112-8.
48. Gracely RH, Schweinhardt P. Key Mechanisms Mediating Fibromyalgia. Rheumatissmo. 2015; In Press.
49. Borsook D, Maleki N, Becerra L, McEwen B. Understanding migraine through the lens of maladaptive stress responses: a model disease of allostatic load. Neuron 2012; 73(2): 219-34.
50. Crawley E. The epidemiology of chronic fatigue syndrome/myalgic encephalitis in children. Arch Dis Child 2013; 99(2): 171-4.
51. Hempel S, Chambers D, Bagnall AM, Forbes C. Risk factors for chronic fatigue syndrome/myalgic encephalomyelitis: a systematic scoping review of multiple predictor studies. Psychol Med 2008; 38(7): 915-26.
52. Jacobson SK, Daly JS, Thorne GM, McIntosh K. Chronic parvovirus B19 infection resulting in chronic fatigue syndrome: case history and review. Clin Infect Dis 1997; 24(6): 1048-51.
53. Lane RJ, Soteriou BA, Zhang H, Archard LC. Enterovirus related metabolic myopathy: a postviral fatigue syndrome. J Neurol Neurosurg Psychiatry 2003; 74(10): 1382-6.
54. Lindh G, Samuelson A, Hedlund KO, Evengard B, Lindquist L, Ehrnst A. No findings of enteroviruses in Swedish patients with chronic fatigue syndrome. Scand J Infect Dis 1996; 28(3): 305-7.
55. Seishima M, Mizutani Y, Shibuya Y, Arakawa C. Chronic fatigue syndrome after human parvovirus B19 infection without persistent viremia. Dermatology 2008; 216(4): 341-6.
56. Cairns V, Godwin J. Post-Lyme borreliosis syndrome: a metaanalysis of reported symptoms. Int J Epidemiol 2005; 34(6): 1340- 5.
57. Cassisi G, Sarzi-Puttini P, Cazzola M. Chronic widespread pain and fibromyalgia: could there be some relationships with infections and vaccinations? Clin Exp Rheumatol 2011; 29(6 Suppl 69): S118-26.
58. Sommer C, Hauser W, Burgmer M, et al. Etiology and pathophysiology of fibromyalgia syndrome. Schmerz 2012; 26(3): 259-67.
59. Markkula R, Jarvinen P, Leino-Arjas P, Koskenvuo M, Kalso E, Kaprio J. Clustering of symptoms associated with fibromyalgia in a Finnish Twin Cohort. Eur J Pain 2009; 13(7): 744-50.
60. Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B. Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome. Rheumatol Int 2001; 21(2): 58-61.
61. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol 2009; 5(7): 374-81.
62. McEwen BS, Biron CA, Brunson KW, et al. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res 1997; 23(1-2): 79-133.
63. Dhabhar FS. Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulat 2009; 16(5): 300-17.
64. Kvetnansky R, Pacak K, Fukuhara K, et al. Sympathoadrenal system in stress. Interaction with the hypothalamic-pituitaryadrenocortical system. Ann N. Y. Acad Sci 1995; 771: 131-58.
65. Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maixner W. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain 2007; 128(3): 199-208.
66. Diatchenko L, Anderson AD, Slade GD, et al. Three major haplotypes of the beta2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder. Am J Med Genet B Neuropsychiatr Genet 2006; 141B(5): 449-62.
67. Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Gen Hum Mol Genet, 2005; 14(1): 135-43.
68. Vossen H, Kenis G, Rutten B, van Os J, Hermens H, Lousberg R. The genetic influence on the cortical processing of experimental pain and the moderating effect of pain status. PloS one 2010; 5(10): e13641.
69. Vargas-Alarcon G, Fragoso JM, Cruz-Robles D, et al. Catechol-Omethyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia. Arthritis Res Ther 2007; 9(5): R110.
70. Xiao Y, He W, Russell IJ. Genetic polymorphisms of the beta2- adrenergic receptor relate to guanosine protein-coupled stimulator receptor dysfunction in fibromyalgia syndrome. J Rheumatol 2011; 38(6): 1095-103.
71. Desmeules J, Piguet V, Besson M, et al. Psychological distress in fibromyalgia patients: a role for catechol-O-methyl-transferase Val158met polymorphism. Health Psychol 2012; 31(2): 242-9.
72. Meeus M, Goubert D, De Backer F, et al. Heart rate variability in patients with fibromyalgia and patients with chronic fatigue syndrome: a systematic review. Semin Arthritis Rheum 2013; 43(2): 279-87.
73. Sommer C, Hauser W, Gerhold K, et al. Etiology and pathophysiology of fibromyalgia syndrome and chronic widespread pain. Schmerz 2008; 22(3): 267-82.
74. Thieme K, Turk DC. Heterogeneity of psychophysiological stress responses in fibromyalgia syndrome patients. Arthritis Res Ther 2006; 8(1): R9.
75. Pollak KA, Swenson JD, Vanhaitsma TA, et al. Exogenously applied muscle metabolites synergistically evoke sensations of muscle fatigue and pain in human subjects. Exp Physiol 2013; 99(2): 368-80.
76. Light AR, Bateman L, Jo D, et al. Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome. J Intern Med 2012; 271(1): 64-81.
77. Khasar SG, Burkham J, Dina OA, et al. Stress induces a switch of intracellular signaling in sensory neurons in a model of generalized pain. J Neurosci 2008; 28(22): 5721-30.
78. Khasar SG, Dina OA, Green PG, Levine JD. Sound stress-induced long-term enhancement of mechanical hyperalgesia in rats is maintained by sympathoadrenal catecholamines. J Pain 2009; 10(10): 1073-7.
79. Russell IJ. Neurohormonal aspects of fibromyalgia syndrome. Rheum Dis Clin North Am 1989; 15(1): 149-68.
80. Torpy DJ, Papanicolaou DA, Lotsikas AJ, Wilder RL, Chrousos GP, Pillemer SR. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. Arthritis Rheum 2000; 43(4): 872- 80.
81. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma and urinary catecholamines in primary fibromyalgia: a controlled study. J Rheumatol 1992; 19(1): 95-7.
82. Khasar SG, McCarter G, Levine JD. Epinephrine produces a betaadrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J Neurophysiol 1999; 81(3): 1104- 12.
83. Tan KS, Nackley AG, Satterfield K, Maixner W, Diatchenko L, Flood PM. Beta2 adrenergic receptor activation stimulates proinflammatory cytokine production in macrophages via PKA- and NF-kappaB-independent mechanisms. Cell Signal 2007; 19(2): 251-60.
84. Hanke ML, Powell ND, Stiner LM, Bailey MT, Sheridan JF. Beta adrenergic blockade decreases the immunomodulatory effects of social disruption stress. Brain Behav Immun 2012; 26(7): 1150-9.
85. Wohleb ES, Hanke ML, Corona AW, et al. beta-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J Neurosci 2011; 31(17): 6277-88.
86. Diatchenko L, Fillingim RB, Smith SB, Maixner W. The phenotypic and genetic signatures of common musculoskeletal pain conditions. Nat Rev Rheumatol 2013; 9(6): 340-50.
87. McBeth J, Silman AJ, Gupta A, et al. Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitaryadrenal stress axis in the onset of chronic widespread musculoskeletal pain: findings of a population-based prospective cohort study. Arthritis Rheum 2007; 56(1): 360-71.
88. Zhang TY, Labonte B, Wen XL, Turecki G, Meaney MJ. Epigenetic mechanisms for the early environmental regulation of hippocampal glucocorticoid receptor gene expression in rodents and humans. Neuropsychopharmacology 2013; 38(1): 111-23.
89. McLean SA, Williams DA, Stein PK, et al. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology 2006; 31(12): 2776-82.
90. McLean SA, Williams DA, Harris RE, et al. Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum 2005; 52(11): 3660-9.
91. McLean SA, Williams DA, Stein PK, et al. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology 2006; 31(12): 2776-82.
92. Tak LM, Cleare AJ, Ormel J, et al. Meta-analysis and metaregression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. Biol Psychol 2011; 87(2): 183-94.
93. Van Houdenhove B. Listening to CFS: why we should pay more attention to the story of the patient. J Psychosom Res 2002; 52(6): 495-9.
94. Chida Y, Steptoe A. Cortisol awakening response and psychosocial factors: a systematic review and meta-analysis. Biol Psychol 2009; 80(3): 265-78.
95. Suzuki A, Poon L, Papadopoulos AS, Kumari V, Cleare AJ. Long term effects of childhood trauma on cortisol stress reactivity in adulthood and relationship to the occurrence of depression. Psychoneuroendocrinology 2014; 50: 289-99.
96. Wingenfeld K, Nutzinger D, Kauth J, Hellhammer DH, Lautenbacher S. Salivary cortisol release and hypothalamic pituitary adrenal axis feedback sensitivity in fibromyalgia is associated with depression but not with pain.J Pain 2010; 11(11): 1195-202.
97. Heim C, Newport DJ, Mletzko T, Miller AH, Nemeroff CB. The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 2008; 33(6): 693-710.
98. Bertorini TE, Perez A. Neurologic complications of disorders of the adrenal glands. Handb Clin Neurol 2014; 120: 749-71.
99. Arlt W, Allolio B. Adrenal insufficiency. Lancet 2003; 361(9372): 1881-93.
100. Henkin RI. The effects of corticosteroids and ACTH on sensory systems. Prog Brain Res 1970; 32: 270-94.
101. Choi CJ, Knutsen R, Oda K, Fraser GE, Knutsen SF. The association between incident self-reported fibromyalgia and nonpsychiatric factors: 25-years follow-up of the Adventist Health Study. J Pain 2010; 11(10): 994-1003.
102. Harel-Meir M, Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Pract Rheumatol 2007; 3(12): 707-15.
103. Mork PJ, Vasseljen O, Nilsen TI. Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trondelag Health Study. Arthritis Care Res (Hoboken) 2010; 62(5): 611-7.
104. Gremese E, Tolusso B, Gigante MR, Ferraccioli G. Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases). Front Immunol 2014; 5: 576.
105. Gouin JP, Glaser R, Malarkey WB, Beversdorf D, Kiecolt-Glaser JK. Childhood abuse and inflammatory responses to daily stressors. Ann Behav Med 2012; 44(2): 287-92.
106. Kiecolt-Glaser JK, Gouin JP, Weng NP, Malarkey WB, Beversdorf DQ, Glaser R. Childhood adversity heightens the impact of laterlife caregiving stress on telomere length and inflammation. Psychosom Med 2011; 73(1): 16-22.
107. Fitzcharles MA, Shir Y, Ablin JN, et al. Classification and Clinical Diagnosis of Fibromyalgia Syndrome: Recommendations of Recent Evidence-Based Interdisciplinary Guidelines. Evid Based Complement Alternat Med 2013; 2013: 528952.
108. Excellence NIfHaC. Diagnosis and management of CFS/ME in adults and children. NICE clinical guideline 53. 2007.
109. Buchwald D, Wener MH, Pearlman T, Kith P. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol 1997; 24(2): 372-6.
110. Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009; 8(4): 287-91.
111. Macedo JA, Hesse J, Turner JD, et al. Adhesion molecules and cytokine expression in fibromyalgia patients: increased L-selectin on monocytes and neutrophils. J Neuroimmunol 2007; 188(1-2): 159-66.
112. Maes M, Libbrecht I, Van Hunsel F, et al. The immuneinflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotrophic cytokines. Psychoneuroendocrinology 1999; 24(4): 371-83.
113. Uceyler N, Valenza R, Stock M, Schedel R, Sprotte G, Sommer C. Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum 2006; 54(8): 2656-64.
114. Maes M. Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry 2009; 22(1): 75- 83.
115. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27(1): 24-31.
116. Dantzer R, Kelley KW. Twenty years of research on cytokineinduced sickness behavior. Brain Behav Immun 2007; 21(2): 153- 60.
117. Ringkamp M, Raja SN, Campbell JN, Meyer RA. Representation of pain in the brain. In: McMahon S, Koltzenburg M, Tracey I, Turk DC, editors. Textbook of Pain. 6th ed: Elsevier-Churchill- Livingstone; 2013. p. 1-30.
118. Mamet J, Lazdunski M, Voilley N. How nerve growth factor drives physiological and inflammatory expressions of acid-sensing ion channel 3 in sensory neurons. J Biol Chem 2003; 278(49): 48907- 13.
119. Light AR, Vierck CJ, Light KC. Myalgia and Fatigue: Translation from Mouse Sensory Neurons to Fibromyalgia and Chronic Fatigue Syndromes. 2011.
120. Grace PM, Hutchinson MR, Maier SF, Watkins LR. Pathological pain and the neuroimmune interface. Nat Rev Immunol 2014; 14(4): 217-31.
121. Borish L, Schmaling K, DiClementi JD, Streib J, Negri J, Jones JF. Chronic fatigue syndrome: identification of distinct subgroups on the basis of allergy and psychologic variables. J Allergy Clin Immunol 1998; 102(2): 222-30.
122. Straus SE, Dale JK, Peter JB, Dinarello CA. Circulating lymphokine levels in the chronic fatigue syndrome. J Infect Dis 1989; 160(6): 1085-6.
123. Baraniuk JN, Casado B, Maibach H, Clauw DJ, Pannell LK, Hess SS. A Chronic Fatigue Syndrome - related proteome in human cerebrospinal fluid. BMC Neurol 2005; 5: 22.
124. Kadetoff D, Lampa J, Westman M, Andersson M, Kosek E. Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 2012; 242(1-2): 33-8.
125. Wohleb ES, Powell ND, Godbout JP, Sheridan JF. Stress-induced recruitment of bone marrow-derived monocytes to the brain promotes anxiety-like behavior. J Neurosci 2013; 33(34): 13820-33.
126. Nair A, Bonneau RH. Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J Neuroimmunol 2006; 171(1-2): 72-85.
127. Sugama S, Takenouchi T, Fujita M, Conti B, Hashimoto M. Differential microglial activation between acute stress and lipopolysaccharide treatment. J Neuroimmunol 2009; 207(1-2): 24-31.
128. Frank MG, Thompson BM, Watkins LR, Maier SF. Glucocorticoids mediate stress-induced priming of microglial proinflammatory responses. Brain Behav Immun 2012; 26(2): 337-45.
129. Serrats J, Schiltz JC, Garcia-Bueno B, van Rooijen N, Reyes TM, Sawchenko PE. Dual roles for perivascular macrophages in immune-to-brain signaling. Neuron 2010; 65(1): 94-106.
130. Wohleb ES, Fenn AM, Pacenta AM, Powell ND, Sheridan JF, Godbout JP. Peripheral innate immune challenge exaggerated microglia activation, increased the number of inflammatory CNS macrophages, and prolonged social withdrawal in socially defeated mice. Psychoneuroendocrinology 2012; 37(9): 1491-505.
131. Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 2013; 30(4): 297-306.
132. Ida T, Hara M, Nakamura Y, Kozaki S, Tsunoda S, Ihara H. Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci Lett 2008; 432(3): 232-6.
133. Matute C, Domercq M, Sanchez-Gomez MV. Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 2006; 53(2): 212-24.
134. Becker S, Schweinhardt P. Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems. Pain Res Treat 2012; 2012: 741746.
135. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992; 35(5): 550-6.
136. Wood PB, Schweinhardt P, Jaeger E, et al. Fibromyalgia patients show an abnormal dopamine response to pain. Euro J Neurosci 2007; 25(12): 3576-82.
137. Cleare AJ, Messa C, Rabiner EA, Grasby PM. Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635. Biol Psychiatry 2005; 57(3): 239-46.
138. Yamamoto S, Ouchi Y, Onoe H, et al. Reduction of serotonin transporters of patients with chronic fatigue syndrome. Neuroreport 2004; 15(17): 2571-4.
139. Hagelberg N, Forssell H, Aalto S, et al. Altered dopamine D2 receptor binding in atypical facial pain. Pain 2003; 106(1-2): 43-8.
140. Hagelberg N, Forssell H, Rinne JO, et al. Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain 2003; 101(1-2): 149-54.
141. Harris RE, Sundgren PC, Craig AD, et al. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum 2009; 60(10): 3146-52.
142. Harris RE, Sundgren PC, Pang Y, et al. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum 2008; 58(3): 903-7.
143. Haroon E, Woolwine BJ, Chen X, et al. IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology 2014; 39(7): 1777-85.
144. Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol 2012; 33(3): 315-27.
145. Capuron L, Pagnoni G, Drake DF, et al. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry 2012; 69(10): 1044-53.
146. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 2000; 20(16): 6309-16.
147. Nagakura Y, Oe T, Aoki T, Matsuoka N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. Pain 2009; 146(1-2): 26-33.
148. Oka T, Aou S, Hori T. Intracerebroventricular injection of interleukin-1 beta enhances nociceptive neuronal responses of the trigeminal nucleus caudalis in rats. Brain Res 1994; 656(2): 236- 44.
149. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest 2010; 120(11): 3779-87.
150. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66(6): 355-474.
151. Chitour D, Dickenson AH, Le Bars D. Pharmacological evidence for the involvement of serotonergic mechanisms in diffuse noxious inhibitory controls (DNIC). Brain Res 1982; 236(2): 329-37.
152. Lapirot O, Melin C, Modolo A, et al. Tonic and phasic descending dopaminergic controls of nociceptive transmission in the medullary dorsal horn. Pain 2011; 152(8): 1821-31.
153. Peng YB, Lin Q, Willis WD. Involvement of alpha-2 adrenoceptors in the periaqueductal gray-induced inhibition of dorsal horn cell activity in rats. J Pharmacol Exp Ther 1996; 278(1): 125-35.
154. Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends in Pharmacol Sci 2004; 25(12): 613-7.